Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details Textual)

v3.19.3
Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 16, 2019
Dec. 31, 2014
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2016
Jun. 30, 2019
Sep. 30, 2014
Stockholders' equity (Textual)              
Preferred stock, par value     $ 0.001     $ 0.001  
Preferred stock, shares authorized     5,000,000     5,000,000  
Preferred stock special voting shares issued     1     1  
Common stock, shares authorized     95,000,000     95,000,000  
Common stock, par value     $ 0.001     $ 0.001  
Common stock, shares issued (in shares)     11,406,233     3,839,358  
Series B preferred stock dividend          
Issue of shares     1,280        
Proceeds from warrants excercised     $ 26,550      
Unvested stock options     560,666        
2017 Omnibus Incentive Plan [Member]              
Stockholders' equity (Textual)              
Common stock, shares issued (in shares)     780,000        
Common stock issued under the 2017 Plan     614,515        
Shares issued for services, shares     165,485        
Stock options exercisable     549,199        
Stock options exercise price     $ 0.61        
Stock options exercisable date, description     September 5, 2029        
Percentage of fully diluted shares of common stock     8.00%        
2017 Omnibus Incentive Plan [Member] | Board of Directors [Member]              
Stockholders' equity (Textual)              
Legacy plan, description     The Company's board of directors approved an increase in the number of shares of common stock available to be issued under the 2017 Plan by 1,500,000. The increase brings the total number of shares available under the 2017 Plan to 2,280,000.        
2017 Omnibus Incentive Plan [Member] | Officers and Directors [Member]              
Stockholders' equity (Textual)              
Legacy plan, description     The Company also granted 1,041,016 stock options to officers and directors of the Company. The total grant date aggregate fair value of the stock options was $505,385. Of the total stock options granted of 1,041,016, 491,817 were granted under the existing 2017 Plan limit and 549,199 will be exercisable subject to approval by the Company's stockholders of the 2017 Plan share increase. All of these stock options granted to officers and directors have an exercise price of $0.61 and expire on September 5, 2029. Of the 1,041,016 stock options granted, 375,000 vest pro rata monthly over one year from the date of grant and 666,016 vest as to one-sixth on the six month anniversary of the grant date with the remaining five-sixths vesting pro rate monthly over 30 months commencing on the seven month anniversary of the grant date.        
Aggregate fair value of the stock options     $ 505,385        
Employee Stock Option [Member]              
Stockholders' equity (Textual)              
Conversion price     $ 15.10        
Stock options exercisable     219,334        
Number of stock options outstanding     780,000     288,183  
Aggregate intrinsic value of stock options outstanding     1,499      
Aggregate intrinsic value of stock options exercisable     $ 0      
Unrecognized compensation expense     $ 352,104        
Unrecognized compensation expense, term     2 years 11 months 4 days        
Unvested stock options     560,666        
Employee Stock Option [Member] | CA$ $20.00 Exercise Price [Member]              
Stockholders' equity (Textual)              
Number of stock options outstanding     2,500        
Employee Stock Option [Member] | $15.27 US$ Exercise Price [Member]              
Stockholders' equity (Textual)              
Number of stock options outstanding     2,500        
Pre Funded Warrants [Member]              
Stockholders' equity (Textual)              
Underwritten public offering, description     The Company granted the underwriters a 45-day option, ending September 28, 2019, to purchase up to an additional 1,012,500 shares of Common Stock and/or 2020 Investor Warrants to purchase up to 1,012,500 shares of Common Stock, at the public offering price less discounts and commissions. On August 15, 2019, the underwriters partially exercised this option by purchasing 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock.        
Warrants are exercisable, per shares     $ 0.01        
Issued warrants to the underwriters     2,655,000        
Proceeds from warrants excercised     $ 26,550        
2020 Investor Warrant [Member]              
Stockholders' equity (Textual)              
Underwritten public offering, description The Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), (ii) pre-funded warrants ("PFW") to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock ("2020 Investor Warrants"), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters' option to purchase additional securities, in the Company's underwritten public offering (the "Offering"). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.            
Underwriting discounts and commissions amount $ 6,582,966            
Warrants are exercisable, per shares $ 1.00            
Expiry date Aug. 16, 2024            
2020 Investor Warrant [Member] | Underwriting Offering [Member]              
Stockholders' equity (Textual)              
Warrants are exercisable, per shares $ 1.15            
Expiry date Aug. 14, 2022            
Underwriter warrants commencing date Feb. 10, 2020            
Issued warrants to the underwriters 377,500            
2020 Investor Warrant [Member] | Pre Funded Warrants [Member]              
Stockholders' equity (Textual)              
Warrants are exercisable, per shares $ 0.01            
Expiry date Aug. 16, 2019            
Series B Preferred Stock [Member]              
Stockholders' equity (Textual)              
Preferred stock, shares issued     648,613     673,613  
Preferred stock, shares outstanding     648,613     673,613  
Preferred stock, rate of dividend         9.00%    
Purchase price of shares         $ 80.00    
Convertible preferred stock         0.25    
Conversion price         $ 32.00    
Conversion of series B preferred stock to common stock, shares     3,700 4,960      
Issue of shares         902,238    
Bid price         $ 8.00    
Final closing date         5 years    
Direct increase in accumulated deficit     $ 2,046 $ 36,085      
Common stock are issuable upon conversion     162,177 220,280      
Liquidation value     $ 5,188,904     $ 5,388,904  
Series B Preferred Stock [Member] | Exchange Agreement [Member]              
Stockholders' equity (Textual)              
Preferred stock, shares outstanding       881,113      
Series A Preferred Stock [Member]              
Stockholders' equity (Textual)              
Preferred stock, shares issued     278,530     278,530  
Preferred stock, shares outstanding     278,530     278,530  
Liquidation value     $ 278,530     $ 278,530  
Series A Preferred Stock [Member] | Exchange Agreement [Member]              
Stockholders' equity (Textual)              
Preferred stock, par value             $ 1
Preferred stock, shares issued             278,530
Preferred stock, rate of dividend   3.00%